Dilution 10/10 · EXTREMEBy ShareStructure Research Desk · Aug 14, 2026
SXTC Has Reverse-Split 1-for-192 Million Since 2021 as Toxic Conversions Cycle
China SXT Pharmaceuticals carries a 10/10 dilution risk score with six reverse splits in five years, roughly $680 million in live shelf and ATM capacity against a $117 million market cap, and a death-spiral prepaid purchase whose floor price sits more than four times above the current share price.